Evidence map›Paper›PMID 38977330›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2024

[Carrier screening for 223 monogenic diseases in Chinese population: a multi-center study in 33 104 individuals].

W Hou, X Fu, X Xie, C Zhang, J Bian, X Mao, J Wen, C Luo, H Jin, Q Zhu and 10 more

Abstract readMulticenter StudyEnglish Abstract
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Application of clinical exome sequencing in sperm donor screening in China.Journal of assisted reproduction and genetics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

W HouMedical School of Chinese People's Liberation Army, Beijing 100853, China.
X FuMedical School of Chinese People's Liberation Army, Beijing 100853, China.
X XieDepartment of Gynecology and Obstetrics, First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
C ZhangMedical Innovation Research Division, Chinese PLA General Hospital, Beijing 100853, China.
J BianZhejiang Biosan Biochemical Technologies Co. Ltd, Hangzhou 310058, China.
X MaoHunan Provincial Maternal and Child Health Care Hospital, Changsha 410008, China.
J WenCenter for Medical Genetics, Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha 410083, China.
C LuoCenter for Medical Genetics, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing 210011, China.
H JinDepartment of Obstetrics and Gynecology, Jinan Maternity and Child Care Hospital, Jinan 250000, China.
Q ZhuDepartment of Medical Genetics, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Q QiDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China.
Y QianDepartment of Reproductive Genetics, Women's Hospital, School of Medicine Zhejiang University, Hangzhou 311215, China.
J YuanCenter for Prenatal Diagnosis, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Y ZhaoDepartment of Clinical Genetics, Shengjing Hospital of China Medical University, Shenyang 110004, China.
A YinDepartment of Gynecology and Obstetrics, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China.
S LiOffice of Standardized Training of Residents, First Affiliated Hospital of Hebei North University, Zhangjiakou 075061, China.
Y JiangDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China.
M ZhangMedical Innovation Research Division, Chinese PLA General Hospital, Beijing 100853, China.
R XiaoZhejiang Biosan Biochemical Technologies Co. Ltd, Hangzhou 310058, China.
Y LuDepartment of Gynecology and Obstetrics, Seventh Medical Center of PLA General Hospital, Beijing 100010, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the epidemiological characteristics and mutation spectrum of monogenic diseases in Chinese population through a large-scale, multicenter carrier screening.

methodsThis study was conducted among a total of 33 104 participants (16 610 females) from 12 clinical centers across China.Carrier status for 223 genes was analyzed using high-throughput sequencing and different PCR methods.

resultsThe overall combined carrier frequency was 55.58% for 197 autosomal genes and 1.84% for 26 X-linked genes in these participants.Among the 16 669 families, 874 at-risk couples (5.24%) were identified.Specifically, 584 couples (3.50%) were at risk for autosomal genes, 306(1.84%) for X-linked genes, and 16 for both autosomal and X-linked genes.The most frequently detected autosomal at-risk genes included GJB2(autosomal recessive deafness type 1A, 393 couples), HBA1/HBA2(α-thalassemia, 36 couples), PAH (phenylketonuria, 14 couples), and SMN1(spinal muscular atrophy, 14 couples).The most frequently detected X-linked at-risk genes were G6PD (G6PD deficiency, 236 couples), DMD (Duchenne muscular dystrophy, 23 couples), and FMR1(fragile X syndrome, 17 couples).After excluding GJB2 c.109G>A, the detection rate of at-risk couples was 3.91%(651/16 669), which was lowered to 1.72%(287/16 669) after further excluding G6PD.The theoretical incidence rate of severe monogenic birth defects was approximately 4.35‰(72.5/16 669).Screening for a battery of the top 22 most frequent genes in the at-risk couples could detect over 95% of at-risk couples, while screening for the top 54 genes further increased the detection rate to over 99%.

conclusionThis study reveals the carrier frequencies of 223 monogenic genetic disorders in the Chinese population and provides evidence for carrier screening strategy development and panel design tailored to the Chinese population.In carrier testing, genetic counseling for specific genes or gene variants can be challenging, and the couples need to be informed of these difficulties before testing and provided with options for not screening these genes or gene variants.

Indexed as

Genetic Carrier Screeningalpha-ThalassemiaChinaConnexin 26ConnexinsEast Asian PeopleFemaleGenetic TestingHeterozygoteHigh-Throughput Nucleotide SequencingHumansMaleMutationConnexin 26ConnexinsGJB2 protein, humangenetic carrier screeninggenetic counselingmonogenic disorders

Identifiers

PMID38977330
PMCPMC11237288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.